Navigating Investment Challenges for Microbiome Drug Development: The Roadmap to Investment

• Introduction to the current microbiome investment landscape and what direction investment is heading in over the next few years.
• Highlighting what investors need to see from emerging companies, how are CSB evaluating companies.
• How should microbiome companies adapt to trends and what should data packages contain.

Sou Miyake, Director of Investment & Business Development, Corundum Systems Biology